Protalix BioTherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLX research report →
Range $6 – $6
Price Chart
About the company
Protalix BioTherapeutics, Inc. , a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
- CEO
- Dror Bashan
- IPO
- 1998
- Employees
- 226
- HQ
- Hackensack, NJ, US
Get TickerSpark's AI analysis on PLX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $244.52M
- P/E
- 11.15
- Fwd P/E
- 11.01
- PEG
- -0.01
- P/S
- 2.89
- P/B
- 2.90
- EV/EBITDA
- 8.11
- Div Yield
- 0.00%
- Gross Margin
- 71.21%
- Op Margin
- 29.76%
- Net Margin
- 24.27%
- ROE
- 30.74%
- ROIC
- 22.35%
Latest fiscal year · YoY change
- Revenue
- $52.74M-1.2%
- Gross Profit
- $25.24M-13.2%
- Op Income
- $-5,500,000
- Net Income
- $-6,604,000-325.2%
- EPS
- $-0.08-308.2%
- OCF Growth
- -238.3%
- FCF Growth
- -284.4%
- 52W High
- $3.19
- 52W Low
- $1.65
- 50D MA
- $2.72
- 200D MA
- $2.45
- Beta
- 0.01
- RSI (14)
- 54
- Avg Volume
- 903.48K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Protalix posted higher 9-month revenue and profit, with Elfabrio momentum and PRX-115 development driving the story.· November 10, 2026
- 9M 2026 revenue rose to $75.6 million, helped mainly by higher Elfabrio sales to Chiesi.
- Q3 2026 revenue was $21.8 million and net income was $4.0 million, or $0.05 per share.
- Cash and short-term deposits increased to $48.5 million, and the company said it has no debt or warrants.
- Management said Chiesi demand is continuing to build, including the new 4-week dosing approval in Europe.
- PRX-115 remains on track: Phase II RELEASE is actively enrolling, with top-line data expected in the second half of next year.
For Q3 2026, total revenues were $21.8 million versus $17.7 million in Q3 2025. Selling-goods revenue was $21.8 million versus $17.7 million. Cost of revenues were $7.9 million versus $8.3 million; R&D was $6.9 million versus $4.5 million; SG&A was $3.1 million versus $2.9 million; financial income, net was $0.6 million versus $0.1 million; taxes on income were $0.7 million versus a $0.1 million tax benefit. Net income was $4.0 million, or $0.05 per share, versus $2.4 million, or $0.03 per share. For the first 9 months of 2026, revenue was $75.6 million versus $43.6 million in the prior-year period, which included a previously reported $25 million milestone payment from Chiesi. Cash, cash equivalents and short-term bank deposits were $48.5 million as of September 30, 2026, up from $40.7 million at June 30, 2026. Management did not provide formal forward guidance for 2027, but said it expects Chiesi growth to continue and will provide 2027 guidance when annual results are published. PRX-115 Phase II RELEASE is actively enrolling, with top-line results expected in the second half of next year.
Dror Bashan framed Elfabrio as the foundation of the business and PRX-115 as the main growth opportunity. He emphasized that the company’s commercial base, cash position, and lack of debt or warrants give it flexibility to advance the pipeline while limiting downside risk. His tone was optimistic and execution-focused, highlighting global expansion for Elfabrio and positioning PRX-115 as potentially best-in-class if it can deliver less frequent dosing with good safety and immunogenicity.
Gilad Mamlok pointed to broad revenue growth, with Q3 revenue of $21.8 million and 9M revenue of $75.6 million, driven mainly by higher Elfabrio sales to Chiesi. He highlighted improving gross margin economics from higher Chiesi revenue, while noting R&D rose to $6.9 million because of RELEASE study subcontractor costs, partly offset by a $1 million R&D law grant. He also noted no debt or warrants and said cash and deposits were $48.5 million at quarter-end, providing financial flexibility.
Analysts focused on how predictable Chiesi revenue is, the impact of the new 4-week Elfabrio dosing, and whether recent results represent a new baseline. Management said Chiesi momentum looks strong and should continue, but declined to give formal 2027 guidance until annual results are published. On PRX-115, management said Phase I data are encouraging, with measurable plasma levels up to 85 days, and described the goal as a less frequent-dosing, safer uricase option for uncontrolled gout. They also said the company will decide this quarter what to do with PRX-119 and will update on timing for any Phase I plan.
The call suggested Elfabrio is still gaining traction, with management seeing continued growth, stronger European penetration, and a meaningful contribution from 4-week dosing. Protalix also ended the quarter with more cash than at the prior quarter-end and no debt or warrants, while advancing PRX-115 in a large unmet-need market.
Management did not provide formal 2027 guidance yet, so investors still lack a clear outlook for next year. R&D spend is rising as RELEASE progresses, and PRX-115 still depends on upcoming clinical data, while PRX-119 timing remains undecided. The company also acknowledged uncertainty on exact adoption levels for 4-week Elfabrio dosing and avoided quantifying future revenue contribution.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.0%
- Shares Outstanding
- 84.32M
- Float Shares
- 76.69M
of shares held by institutions
110 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.20M | ▲ 154.09K |
| State Street Corp | 1.16M | ▲ 173.54K |
| Geode Capital Management, LLC | 997.13K | ▲ 17.13K |
| Renaissance Technologies LLC | 988.10K | ▼ 107.90K |
| Goldman Sachs Group Inc | 889.35K | ▲ 413.43K |
| Northern Trust Corp | 831.73K | ▼ 90.61K |
| Dimensional Fund Advisors LP | 716.99K | ▲ 223.56K |
| Vanguard Portfolio Management LLC | 557.20K | ▲ 46.56K |
| Vanguard Group Inc | 488.55K | ▲ 24.13K |
| Stratos Wealth Partners, Ltd. | 400.00K | ▼ 100.00K |
| Creative Planning | 375.36K | ▲ 375.36K |
| Strs Ohio | 332.50K | ▲ 36.40K |
Held by 80 ETFs
Biggest fund positions in PLX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 3, 26 | Schwartz Aharon | other | 17,000 |
| Sep 3, 26 | Schwartz Aharon | other | 8,500 |
| Sep 3, 26 | Naos Yaron | other | 112,000 |
| Sep 3, 26 | Naos Yaron | other | 56,000 |
| Sep 3, 26 | Elze Christian | other | 17,000 |
| Sep 3, 26 | Melincoff Gwen A | other | 17,000 |
| Sep 3, 26 | Melincoff Gwen A | other | 8,500 |
| Sep 3, 26 | Elze Christian | other | 8,500 |
| Sep 3, 26 | Boudes Pol F | other | 17,000 |
| Sep 3, 26 | Boudes Pol F | other | 8,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PLX coverage
Recent articles, reports, and earnings notes.
No research on PLX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PLX report →Protalix BioTherapeutics, Inc. (PLX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
prnewswire.com · Nov 10
Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
globenewswire.com · Nov 9
Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations
prnewswire.com · Nov 9
Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026
prnewswire.com · Nov 3
Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
prnewswire.com · Sep 8
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.